BRAF and neoplasm: We have found, that hypomethylation within a specific CpG identified in our study is related to both overall and disease free survival following adjuvant FU/LV based therapy; however this may be a phenomenon related to the fact that these tumours are BRAF mutated and thus will have a poorer survival, however we took account of this in our regression model and TFAP2E methylation change still remained significant.